MannKind Corporation

MannKind looks to meet with the FDA in 1H 2025 on the heels of successfully completing its Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including IPF. Nintedanib DPI was shown to be safe and well tolerated in healthy volunteers, meeting its primary objective. Participants did not experience typical adverse events – specifically, no GI or neurological AEs – seen with oral nintedanib. More details: https://bit.ly/48xsNUu #MNKD #Pulmonary #PulmonaryFibrosis #IPF

Our people are the reason we get to celebrate #CertificationNationDay! Thanks Mannitarians for being the driving force that helped us earn Great Place To Work® certification for the second straight year. #iWorkForMNKD #GPTW #GPTWcertified #WorkCulture

Meet with our team at this year’s @IDWeek conference in Los Angeles, October 16-19. MannKind looks forward to discussing our pipeline progression including the ICoN-1 study of Clofazimine Inhalation Suspension for nontuberculous mycobacterial (NTM) lung disease. #MNKD #Pulmonary #NTM #IDWeek2024

Our Mannitarians were abuzz in Danbury this week to install a 2,000 sq. ft. garden to add to Connecticut’s Pollinator Pathway. Pollinators play a critical role in our ecosystem enabling plants in our yards, parks, farms and orchards to reproduce. MannKind is proud to bring 480 plants to its headquarters to create a pollinator-friendly habitat and food source for bees, butterflies, and other pollinating insects and wildlife to eat, drink and rest for years to come. #MannKind #ProudToBeMNKD #PollinatorPathway

MannKind is at the 3rd Epithelial Mesenchymal Interactions in Lung Development and Fibrosis Conference underway in St. Julian’s, Malta. MannKind is sharing a poster as well as a presentation by Dr. Wassim Fares, SVP, Therapeutic Area Head, Orphan Lung on Sunday, October 6 at 6:05 p.m. (CET). Dr. Fares will be discussing “A Novel Dry Powder Delivery Platform: Applications in Pulmonary Fibrosis.” MannKind is currently progressing its Phase 1 study of Nintedanib DPI for fibrotic lung diseases, starting with idiopathic pulmonary fibrosis. #MNKD #Pulmonary #PulmonaryFibrosis #IPF #FusionLung24

Show up and do right – a motto our Mannitarians own day-in and day-out. This past weekend was especially meaningful as TEAM MannKind participated at two Breakthrough T1D events – a Ride in Idaho and a Walk in Connecticut – raising more than $90k to help support finding a cure for type 1 diabetes. It’s about the patient first and MannKind is dedicated to helping them live life more humann®. #MannKind #ProudToBeMNKD #Diabetes #T1D @BreakthroughT1Dwalk @BreakthroughT1Dride #WeRideOn

The 30-week results are in from the INHALE-3 study and MannKind shares a positive update that expands upon 17-week data reported earlier this year. Switching to, or remaining on Afrezza allowed twice as many people to get to goal during the extension phase. Read more here: https://bit.ly/3zeRJTe #MannKind #Diabetes #T1D

Bikes checked. Geared up. Roll out ready! TEAM MannKind is excited to be in picturesque Coeur d’Alene, Idaho to tackle up to 100 miles at the 2024 Breakthrough T1D Ride getting underway Saturday, September 28. A team of 12 Mannitarians are proud to represent as they travel through forested roads, rolling hills and passing through the shorelines of multiple area lakes dotting the course. For MannKind and the countless other riders, the effort isn't just about cycling - it's part of a movement committed to finding cures for type 1 diabetes (T1D). Go TEAM MannKind! #MannKind #ProudToBeMNKD #Diabetes #T1D #BreakthroughT1Dride #WeRideOn

We're on the lookout for passionate and driven interns to join our team for Summer 2025! Our Internship Program offers valuable experiences in various departments including Manufacturing, Engineering, Marketing, Quality, Finance and R&D. Located in Westlake Village, CA, Danbury, CT, and Boston, MA, our 10 - 12-week onsite program is sure to provide an unparalleled opportunity to kickstart a career in the pharmaceutical industry. To learn more about the program visit https://bit.ly/3zwXRqp #WeAreMNKD #ProudToBeMNKD

MannKind is proud to share an update on our efforts of Clofazimine Inhalation Suspension for the potential treatment of NTM lung disease. It was announced today that we received clearance from the PMDA to initiate a Phase 3 clinical trial (ICoN-1) in Japan, and also received clearance to proceed from health authorities in South Korea and Australia. The study is currently underway in the U.S. with the first patient now randomized. Details of the ICoN-1 study and sites can be found at ClinicalTrials.gov (NCT06418711). #MannKind #NTMlungDisease #Pulmonary